ThromboGenics has still an uptrend and is going toward its highest level.

The company’s fundamentals are still strong. Analysts from Thomson Reuters consensus have revised largely upward their EPS estimates (EUR 1.27 for the fiscal year).

Technically, the security is in an uptrend on all time scales and it is supported by moving averages. The bullish trend will not be stopped until prices are above the EUR 30.38 short term support. This trend should allow the stock to reach its EUR 38.2 mid term resistance, which will be the first target price.

According to both technical and fundamental elements, it seems opportune to take a long position at the current price. The bullish trend should allow the security to reach the EUR 38.2 resistance. If the stock crosses it, a new target price will be set. A stop loss will be placed under the EUR 31.5 to avoid a downtrend.